
Sign up to save your podcasts
Or


Are you able to explain the difference between inflammatory bowel disease (IBD) and inflammatory bowel syndrome (IBS)? Test your knowledge with Dr. Jennifer Caudle and Dr. Neil Nandi, who tackles the common misconception that IBD and IBS are the same condition by providing essential tips for diagnosing and treating each of them.
Join Dr. Neilanjan Nandi as he discusses his experiences with patients presenting with GI issues, key symptoms to be on the lookout for, and how primary care clinicians and gastroenterologists can work together with their IBD patients to provide optimal care.
The evolution of therapies for inflammatory bowel disease (IBD) has been nothing short of remarkable, which means it’s time that we take stock of the latest treatment targets, disease mechanism updates, drug pipeline developments, and patient safety considerations. And here to help us do just that is Dr. Jill Gaidos, Associate Professor of Medicine in the Division of Gastroenterology, Hepatology, and Nutrition at Virginia Commonwealth University.
Real-world Pattern of Biologic Use in Patients With Inflammatory Bowel Disease: Treatment Persistence, Switching, and Importance of Concurrent Immunosuppressive Therapy
Chao Chen, PhD, Abraham G Hartzema, PhD, Hong Xiao, PhD, Yu-Jung Wei, PhD, Naueen Chaudhry, MD, Ofor Ewelukwa, MD, Sarah C Glover, DO, Ellen M Zimmermann, MD
BACKGROUND AND AIMS:
Medication persistence, defined as the time from drug initiation to discontinuation of therapy, has been suggested as a proxy for real-world therapeutic benefit and safety. This study seeks to compare the persistence of biologic drugs among patients with inflammatory bowel disease (IBD).
METHODS:
Patients with newly diagnosed IBD were included in a retrospective study using Truven MarketScan database. Treatment persistence and switching was compared among biologic medications including infliximab, adalimumab, certolizumab, golimumab, and vedolizumab. Predictors for discontinuation and switching were evaluated using time-dependent proportional hazard regression.
RESULTS:
In total, 5612 patients with Crohn's disease (CD) and 3533 patients with ulcerative colitis (UC) were included in this analysis. Less than half of the patients continued using their initial biologic treatment after 1 year (48.48% in CD cohort; 44.78% in UC cohort). …
Improving the Quality of Inpatient Ulcerative Colitis Management: Promoting Evidence-Based Practice and Reducing Care Variation With an Inpatient Protocol
Sara M Lewin, MD, Ryan A McConnell, MD, Roshan Patel, MD, Suzanne R Sharpton, MD, MAS, Fernando Velayos, MD, MPH, Uma Mahadevan, MD
BACKGROUND:
Hospitalization for ulcerative colitis is a high-risk period associated with increased risk of Clostridium difficile infection, thromboembolism, and opiate use. The study aim was to develop and implement a quality-improvement intervention for inpatient ulcerative colitis management that standardizes gastroenterology consultant recommendations and improves delivery of evidence-based care.
METHODS:
All adult patients hospitalized for ulcerative colitis between July 1, 2014, and December 31, 2017, who received intravenous corticosteroids were included. On July 1, 2016, the UCSF Inpatient Ulcerative Colitis Protocol was implemented, featuring standardized core recommendations and a daily checklist for gastroenterology consultant notes, a bundled IBD electronic order set, and an opiate awareness campaign. The composite primary outcome was adherence to all 3 evidence-based care metrics: C. difficile testing performed, pharmacologic venous thromboembolism (VTE) prophylaxis ordered, and opiates avoided.
RESULTS:
Ninety-three ulcerative colitis hospitalizations occurred, including 36 preintervention and 57 postintervention. Age, gender, …
Biosimilar medications have now entered the clinical landscape of treatment protocols for several disciplines—including gastroenterology. Joining Dr. Thomas Ullman to discuss the biosimilars that are available for Crohn’s disease and ulcerative colitis and how other parts of the world are using them are Dr. Sarah Yim, Acting Director of the Office of Therapeutic Biologics & Biosimilars, and Dr. Juli Tomaino, a pediatric gastroenterologist and Lead Medical Officer at the FDA.
To gain more insights into how inflammatory bowel disease (IBD) affects our young patients, Dr. Jennifer Caudle connects with Caroline, a 12-year-old patient who was diagnosed with IBD at the age of 4, and her parents, Preston and Rachelle, about the challenges they face and the strategies and solutions available that can help children and teens like Caroline manage this condition.
Recorded live at the American Medical Association’s meeting on the new value-based approach to primary care, Alex Azar and Seema Verma take turns explaining the CMS Primary Cares initiative, which aims to put the focus back on keeping patients healthy as opposed to ordering procedures.
As the 24th Secretary of the Department of Health and Human Services, Alex Azar is pursuing four objectives, including lowering prescription drug prices and making individual insurance more affordable, while Seema Verma as the Administrator of the Centers for Medicare and Medicaid Services is working towards improving E/M codes to save providers’ time and money.
Higher Postinduction Infliximab Serum Trough Levels Are Associated With Healing of Fistulizing Perianal Crohn’s Disease in Children.
Wael El-Matary, MD, MSc Thomas D Walters, MD Hien Q Huynh, MDJennifer deBruyn, MD David R Mack, MD Kevan Jacobson, MD Mary E Sherlock, MDPeter Church, MD Eytan Wine, MD, PhD Matthew W Carroll, MD, Eric I Benchimol, MD, PhD Sally Lawrence, MD Anne M Griffiths, MD
Background:There is some evidence in adults that higher serum infliximab (IFX) levels are needed to adequately treat fistulizing perianal Crohn's disease (CD). However, data in children are lacking. We aimed to determine postinduction serum trough IFX levels that are associated with healing of fistulizing perianal CD (PCD) at week 24.
Methods:In a multicenter inception cohort study, consecutive children younger than age 17 years with fistulizing perianal CD treated with IFX between April 2014 and June 2017 who had serum trough IFX titers measured before the fourth infusion were included. Area under the receiver operating characteristic curve (AUROC) was calculated to determine the best cutoff to predict fistula …
Impact of Obesity on Short- and Intermediate-Term Outcomes in Inflammatory Bowel Disease: Pooled Analysis of Placebo Arms of Infliximab Clinical Trials.
Siddharth Singh, MD, MS James Proudfoot, MS Ronghui Xu, PhDWilliam J Sandborn, MD
Background:To assess whether obesity may affect natural history of inflammatory bowel diseases (IBD), we conducted an individual participant data (IPD) pooled analysis of placebo arms, using data from clinical trials of infliximab in IBD and using the Yale Open Data Access (YODA) Project.
Methods:We obtained IPD from 4 placebo-controlled trials of infliximab in adults with IBD (ACCENT-I and ACCENT-II; ACT-1 and ACT-2). Patients were categorized into quartiles based on body mass index (BMI) or weight at time of trial entry. Primary outcome was clinical remission (Crohn’s disease activity index [CDAI]<150, Mayo Clinic Score <3); secondary outcomes were clinical response and mucosal healing. Using multivariable logistic regression analysis, we compared association between quartiles of BMI (or weight) and achieving remission, after adjusting for sex, smoking, disease activity, and concomitant prednisone or immunomodulators.
Results:We included 575 placebo-treated patients (mean age 38 years, 51.6% males, 16% obese). Obesity was not associated with odds of achieving clinical …
From the publisher's feed